Analysts await Revance Therapeutics, Inc. (NASDAQ:RVNC) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $-0.87 EPS, down 25.29% or $0.22 from last year’s $-0.65 per share.

At the moment 6 analysts are watching Revance Therapeutics, Inc. (NASDAQ:RVNC), 3 rate it “Buy”, 3 “Outperform”, 0 “Underperform”, 0 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Jun-16, 5 analysts have a mean sales target of 0.07 million. For the quarter ending Sep-16, 5 analysts have a mean sales target of 0.07 million whilst for the year ending Dec-16, 6 analysts have a mean target of 0.18 million.

In terms of earnings per share, 5 analysts have a -0.87 EPS mean target for the quarter ending Jun-16, for the quarter ending Sep-16, 5 analysts have a -0.95 EPS mean target and for the quarter ending Sep-16 there are 6 estimates of -3.67 EPS.

The biggest institutional shareholders in Revance Therapeutics, Inc. include Essex Woodlands Health Ventures which owns 5 million shares in the company valued at $156.86 million. Essex Woodlands Health Ventures, Inc is the second biggest holder with 5 million shares currently valued at 156.86 million whilst Franklin Advisers, Inc. has 3 million shares valued at 108.59 million.

Total shares held by institutions as of the most recent company filings are 35,793,947 with a reported 4,395,087 bought and 215,105 sold. These holdings make up 99.23% of the company’s outstanding shares.

Currently insiders hold 397,425 shares in the business which makes up 1.40% of shares. The biggest holder currently is Mr. L. Daniel Browne who owns 243,677 shares (0.86% of those outstanding), whilst Dr. Abhay Joshi, M.B.A.,PhD holds 34,375 (0.12% of shares outstanding) and Arthur Peter Bertolino holds 34,001 (0.12% of shares outstanding).

The stock decreased 2.22% or $0.37 during the last trading session.